Please assess the completion status of the following clinical trial:

Trial Title: SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients with chronic low platelet count (less than 30,000/µL) for 6 months who have failed at least one treatment for chronic low platelet count.~* Patients receiving chronic maintenance steroid therapy must have received a stable dose for at least 1 month.~* Normal PT and PTT.~Exclusion criteria:~* History of clotting disorder.~* Females who are pregnant or are receiving hormone replacement therapy or systemic contraceptives.~* History of alcohol/drug abuse or dependence within 1 year.~* Use of aspirin, aspirin-containing compounds, salicylates, antacids, rosuvastatin, pravastatin, non-steroidal anti-inflammatory drugs during the study and within 3 weeks prior to starting the study.~* History of HIV infection or active infection with Hepatitis B or C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).